EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

David Ledingham iD, Sahana Sathyanarayana, Charlotte B Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von David Ledingham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Ageing Research Unit, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Disease Progression. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.

Methods

We analysed 1205 individuals with sporadic and genetic Parkinson's disease from the Parkinson's Progression Markers Initiative (mean follow‐up: 5.6 ± 4.3 years). Kaplan–Meier analysis estimated time to meeting the 5‐2‐1 criteria (five or more daily levodopa doses, two or more hours of OFF time, or one or more hours of troublesome dyskinesia) and a stricter definition of eligibility for device‐aided therapy based on disabling, medication‐refractory symptoms and/or tremor. In the sporadic Parkinson's disease subgroup ( n = 943), we assessed therapy initiation and clinical suitability, including potential contraindications. Genetic subgroup analyses explored differences in progression, eligibility timing and treatment uptake.

Results

Among individuals with sporadic Parkinson's disease, 257 (27.3%) met the 5‐2‐1 criteria, with 25%, 50% and 75% doing so by 5.3, 8.2 and 10.7 years, respectively. A total of 176 (18.6%) met stricter eligibility criteria, with 50% doing so by 12 years. Only 25% of those meeting the 5‐2‐1 criteria initiated device‐aided therapy within 6.8 years. Most had no contraindications. Deep brain stimulation was the most used therapy. GBA and SNCA carriers met criteria earlier. LRRK2 carriers were more likely to initiate therapy, while PRKN carriers were less likely to meet eligibility thresholds.

Interpretation

Eligibility for device‐aided therapy is common but underutilised. These findings highlight missed opportunities and support earlier, genotype‐informed treatment planning in Parkinson's disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDisease ProgressionHumansMaleFemaleAgedMiddle AgedAntiparkinson AgentsLevodopa

Stichwörter der Autor:innen

Parkinson's diseasedevice‐aided therapygenetic subgroupslongitudinal analysismotor complications

Substanzen

Antiparkinson AgentsLevodopa

Autor:innen und Institutionen

  • Clinical Ageing Research Unit, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.
  • Neurosciences, Newcastle Upon Tyne NHS Foundation Trust, Newcastle Upon Tyne, UK.
  • Translational and Clinical Research Institute, the Medical School, Newcastle University, Newcastle Upon Tyne, UK.
  • Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: David Ledingham

Zitieren

APA

Ledingham, D., Sathyanarayana, S., Stewart, C. B., Iredale, R., Foster, V., Galley, D., Baker, M., & Pavese, N. (2025). Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70188

Vancouver

Ledingham D, Sathyanarayana S, Stewart CB, Iredale R, Foster V, Galley D, et al. Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70188

BibTeX
@article{Ledingham2025,
  author = {Ledingham, David and Sathyanarayana, Sahana and Stewart, Charlotte B and Iredale, Robyn and Foster, Victoria and Galley, Debra and Baker, Mark and Pavese, Nicola},
  title = {Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70188}
}
Kostenlos starten →